Search
Ridaforolimus
go.drugbank.com/drugs/DB06233InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. Most standard CMV therapies, such as ganciclovir or foscarnet, target CMV DNA polymerase - ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAvanafil
go.drugbank.com/drugs/DB06237ApprovedAvanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but l...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesrPSGL-Ig
go.drugbank.com/drugs/DB06256InvestigationalRecombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.
Synonyms: Recombinant P-selectin glycoprotein ligand-immunoglobulin IgColtuximab ravtansine
go.drugbank.com/drugs/DB06342InvestigationalColtuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAvasimibe
go.drugbank.com/drugs/DB06442ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InducersDotarizine
go.drugbank.com/drugs/DB06446ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRemacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPropentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMuraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates